Open access

Plasma P‐tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease

Emily C. Collins M. Lu Rose C. Beck J. Hendrix Michael E. Hodsdon O. Hansson

Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 49 references

Medicine

Abstract

This analysis of the phase 3 TRAILBLAZER‐ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p‐tau217) level can reliably monitor treatment‐related amyloid clearance (TRAC) after donanemab treatment in early symptomatic Alzheimer's disease (AD).

DOI PubMed Semantic Scholar

Read PDF